Profitability Ratios
| Ratio |
Value |
| GP Margin |
93.4% |
| EBIT Margin |
-3959.4% |
| EBITDA Margin |
-3901.0% |
| Operating Margin |
-4350.1% |
| Pretax Margin |
-3959.4% |
| Cont. Ops Margin |
-3959.4% |
| Net Margin |
-3959.4% |
| Bottom Line Margin |
-3959.4% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
0.84 |
| Quick Ratio |
0.84 |
| Solvency Ratio |
-3.769 |
| Cash Ratio |
0.41 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.02 |
| Forward PEG |
-0.02 |
| Price/Book |
29.75 |
| Price/Sales |
29.50 |
| Price/FCF |
-0.97 |
| Price/Op Cash Flow |
-0.98 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0000 |
| Debt/Equity |
0.0000 |
| Debt/Capital |
0.0000 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
11.44 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.11 |
| Operating Cash Flow Ratio |
-2.898 |
| Operating Cash Flow/Sales |
-2999.4% |
| Free Cash Flow/Operating Cash Flow |
101.1% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
0.00 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
0.00 |
| Capital Expenditure Coverage |
-92.95 |
| Dividend + Capital Expenditure Coverage |
-92.95 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.80 |
| EPS |
-31.673 |
| Debt/Share |
0.0000 |
| Cash/Share |
6.57 |
| Book Value/Share |
0.79 |
| Tangible BV/Share |
-0.39 |
| Equity/Share |
0.79 |
| Operating Cash Flow/Share |
-23.994 |
| Capital Expenditure/Share |
0.258 |
| FCF/Share |
-24.252 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
0.910 |
| Price/Fair Value |
29.75 |
| Debt/Market Cap |
0.0000 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-0.65 |
BRTX - BioRestorative Therapies, Inc.